Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRSN |
---|---|---|
09:32 ET | 2466 | 1.85 |
09:34 ET | 7018 | 1.85 |
09:38 ET | 2777 | 1.85 |
09:41 ET | 1680 | 1.86 |
09:48 ET | 200 | 1.85 |
09:52 ET | 10842 | 1.845 |
09:54 ET | 700 | 1.85 |
09:56 ET | 1150 | 1.85 |
09:57 ET | 2000 | 1.85 |
09:59 ET | 23148 | 1.85 |
10:01 ET | 6350 | 1.8499 |
10:03 ET | 2357 | 1.85 |
10:06 ET | 709 | 1.85 |
10:08 ET | 16043 | 1.84 |
10:10 ET | 6286 | 1.845 |
10:12 ET | 3000 | 1.86 |
10:14 ET | 1300 | 1.865 |
10:15 ET | 869 | 1.87 |
10:17 ET | 1200 | 1.8807 |
10:19 ET | 1501 | 1.895 |
10:21 ET | 500 | 1.89 |
10:24 ET | 3678 | 1.885 |
10:26 ET | 300 | 1.885 |
10:28 ET | 300 | 1.88 |
10:30 ET | 300 | 1.875 |
10:32 ET | 800 | 1.86 |
10:33 ET | 400 | 1.87 |
10:35 ET | 600 | 1.865 |
10:42 ET | 741 | 1.86 |
10:48 ET | 100 | 1.855 |
10:50 ET | 198 | 1.855 |
11:00 ET | 22368 | 1.85 |
11:02 ET | 1367 | 1.85 |
11:04 ET | 700 | 1.85 |
11:06 ET | 600 | 1.85 |
11:08 ET | 3427 | 1.845 |
11:09 ET | 1783 | 1.854 |
11:11 ET | 411 | 1.855 |
11:13 ET | 100 | 1.855 |
11:20 ET | 1140 | 1.85 |
11:24 ET | 1712 | 1.855 |
11:26 ET | 2830 | 1.859 |
11:27 ET | 1088 | 1.855 |
11:29 ET | 548 | 1.855 |
11:31 ET | 1788 | 1.85 |
11:33 ET | 100 | 1.85 |
11:36 ET | 100 | 1.85 |
11:38 ET | 700 | 1.855 |
11:47 ET | 400 | 1.853057 |
11:49 ET | 100 | 1.85 |
11:51 ET | 100 | 1.85 |
11:54 ET | 2482 | 1.85 |
11:56 ET | 4388 | 1.855 |
11:58 ET | 9883 | 1.8475 |
12:00 ET | 8419 | 1.85 |
12:02 ET | 6400 | 1.855 |
12:03 ET | 400 | 1.855 |
12:05 ET | 2362 | 1.86 |
12:18 ET | 100 | 1.86 |
12:20 ET | 100 | 1.86 |
12:21 ET | 5888 | 1.87 |
12:23 ET | 3086 | 1.865 |
12:27 ET | 300 | 1.86 |
12:30 ET | 100 | 1.86 |
12:32 ET | 100 | 1.86 |
12:34 ET | 100 | 1.86 |
12:36 ET | 1405 | 1.864 |
12:38 ET | 600 | 1.855 |
12:41 ET | 100 | 1.855 |
12:48 ET | 100 | 1.855 |
12:50 ET | 407 | 1.855 |
12:52 ET | 400 | 1.855 |
12:54 ET | 15162 | 1.84 |
12:56 ET | 1300 | 1.8475 |
12:57 ET | 868 | 1.85 |
12:59 ET | 2256 | 1.85 |
01:01 ET | 1512 | 1.85 |
01:03 ET | 1600 | 1.85 |
01:10 ET | 267 | 1.8599 |
01:14 ET | 5515 | 1.855 |
01:15 ET | 334 | 1.855 |
01:19 ET | 1100 | 1.86 |
01:24 ET | 300 | 1.86 |
01:28 ET | 113 | 1.87 |
01:30 ET | 800 | 1.86 |
01:32 ET | 100 | 1.85 |
01:44 ET | 208 | 1.85 |
01:51 ET | 9045 | 1.855 |
01:53 ET | 200 | 1.855 |
01:55 ET | 1500 | 1.86 |
02:09 ET | 100 | 1.86 |
02:13 ET | 300 | 1.865 |
02:18 ET | 100 | 1.865 |
02:20 ET | 1040 | 1.86 |
02:27 ET | 100 | 1.855 |
02:29 ET | 200 | 1.85 |
02:33 ET | 300 | 1.855 |
02:36 ET | 100 | 1.85 |
02:38 ET | 21878 | 1.85 |
02:44 ET | 1052 | 1.8508 |
02:45 ET | 200 | 1.85 |
02:51 ET | 100 | 1.85 |
02:54 ET | 300 | 1.85 |
02:56 ET | 1547 | 1.855 |
02:58 ET | 100 | 1.85 |
03:02 ET | 200 | 1.85 |
03:03 ET | 339 | 1.85 |
03:05 ET | 300 | 1.855 |
03:14 ET | 200 | 1.855 |
03:16 ET | 196 | 1.855 |
03:23 ET | 500 | 1.855 |
03:25 ET | 200 | 1.855 |
03:27 ET | 100 | 1.855 |
03:30 ET | 899 | 1.85 |
03:34 ET | 100 | 1.84 |
03:43 ET | 317 | 1.84 |
03:45 ET | 1300 | 1.85 |
03:48 ET | 300 | 1.845 |
03:50 ET | 285 | 1.845 |
03:52 ET | 488 | 1.84 |
03:54 ET | 714 | 1.845 |
03:56 ET | 1300 | 1.845 |
03:57 ET | 8104 | 1.835 |
03:59 ET | 97906 | 1.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mersana Therapeutics Inc | 229.4M | -2.1x | --- |
Nanobiotix SA | 201.9M | -3.5x | --- |
Artiva Biotherapeutics Inc | 246.5M | 0.0x | --- |
Caribou Biosciences Inc | 178.0M | -1.4x | --- |
Compugen Ltd | 146.8M | -15.0x | --- |
TScan Therapeutics Inc | 250.6M | -4.3x | --- |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.4M |
---|---|
Revenue (TTM) | $29.9M |
Shares Outstanding | 122.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-0.86 |
Book Value | $0.31 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 7.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -373.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.